glp·helper
glphelper.com/tirzepatide/california/hanford
Dual GIP / GLP-1 receptor agonistFDA-approved May 2022 (Mounjaro) · November 2023 (Zepbound)Rx · Subcutaneous injection · Once weekly

Tirzepatide® providers &
prescriptions in Hanford, CA

Verified Tirzepatide providers in Hanford, CA. Checked against the NPI registry, never ranked by who pays us.[7]

city providers
27
as of today
§ 02Provider directory: California
27 of 27 shown

Find a Tirzepatide provider in California.

Every entry is checked against the federal NPI registry. We do not accept payment for placement.

Filter →
Type
Provider
City
Insurance / phone
Browse by California city · /tirzepatide/california/{city}
§ 03Getting Tirzepatide in Hanford
27 providers · Hanford, CA

How to get Tirzepatide in Hanford.

27 GLP-1 prescribers and 7 local resource types are on record for Hanford, plus 3 nearby towns in the directory.

Prescribers in Hanford
27 prescribers
27 GLP-1 prescribers in Hanford, most listed as Family Medicine (14), Internal Medicine (11) and Internal Medicine, Endocrinology, Diabetes & Metabolism (1). Any California-licensed physician, nurse practitioner, or PA can prescribe Tirzepatide, over video or in person. The nearest towns on record are Visalia (28 providers), Tulare (29 providers) and Fresno (41 providers).
Around the prescription in Hanford
7 listed nearby
30 dietitians, 6 nutritionists, 6 gyms, 4 fitness clubs, 2 trainers, 6 physiotherapists and 1 places to move are on record near Hanford.
Medicaid (weight loss)
Diabetes only
As of April 2026, California Medicaid covers GLP-1s for diabetes but not for weight loss. Employer and private plans can still cover them; that is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm California’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

The molecule in Mounjaro and Zepbound. It acts on two gut-hormone pathways, GIP and GLP-1.

Tirzepatide is a once-weekly injection sold by Eli Lilly as Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management). It is the first approved dual GIP/GLP-1 receptor agonist. It activates two gut-hormone pathways rather than one, which is associated with greater average weight loss than single GLP-1 agonists.[2][3]

In SURMOUNT-1, adults with obesity (without diabetes) lost a mean of 20.9% of body weight on the 15 mg dose at 72 weeks, versus 3.1% on placebo. In the SURPASS-2 head-to-head diabetes trial, tirzepatide produced larger HbA1c and weight reductions than semaglutide 1 mg.[1]

At a glanceMultiple (brand-specific)
Generic name
tirzepatide
Drug class
Dual GIP / GLP-1 receptor agonist
Manufacturer
Eli Lilly
FDA approved
May 2022 (Mounjaro) · November 2023 (Zepbound)
Approved use
Type 2 diabetes (Mounjaro) · chronic weight management (Zepbound)
Off-label use
Use outside the approved brand/indication is off-label
Administration
Subcutaneous injection · Once weekly
Available doses
2.5 mg · 5 mg · 7.5 mg · 10 mg · 12.5 mg · 15 mg
Half-life
≈ 5 days
Pregnancy
Discontinue ≥ 2 months before a planned pregnancy; may reduce oral contraceptive efficacy

Community health · CDC

Weight & metabolic health in Hanford

Hanford, California has a population of 57,990 people. The adult obesity rate in Hanford is an age-adjusted estimate of 33.6%, 4.5 percentage points above the California state rate of 29.1%. Diagnosed diabetes reaches 11.7% of adults in Hanford. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 28.7% of adults in Hanford.

of Hanford adults have obesity
33.6%
diagnosed diabetes
11.7%
no regular physical activity
28.7%

Age-adjusted estimates for Hanford, community figures, not individual risk. CDC PLACES, 2025 release.

Estimate your weight lossOzempic side effects in men
§ 05Support around Tirzepatide in Hanford
4 nutritionists

The prescription is one part. Here is the rest, in Hanford.

Trials of tirzepatide paired the drug with diet counseling and regular activity. Every name below is a real listing near Hanford, CA, ordered as the registry lists them, never by who pays us.

Nutritionists

A nutritionist helps you get enough protein and fiber while the medication cuts your appetite. Call to ask what they cover.

Julie Azevedo, RN CDE
NUTRITIONIST
Nutritionist · Education
515 W Grangeville Blvd
Call 208-944-4306NPI 1568082220
Olivia Hickey, MSCN
NUTRITIONIST
Nutritionist · Education
1961 S Courtright Ave
Call 925-382-8662NPI 1740006493
Lisa Paolucci-Monteleone, RN CDE
NUTRITIONIST
Nutritionist · Education
515 W Grangeville Blvd
Call 928-247-7309NPI 1598385106
Susan Smith, PHD, CDE
NUTRITIONIST
Nutritionist · Education
515 W Grangeville Blvd
Call 928-247-7309NPI 1427686450

Gyms near you

A gym gives you the regular movement that keeps muscle while the weight comes off.

Planet Fitness
GYM
4.3 on Google · 378 reviews
1919 W Lacey Blvd
Website
Just Lift
GYM
4.0 on Google · 230 reviews
522 W 7th St
Website
Hanford Cali Fitness
GYM
4.9 on Google · 43 reviews
330 E 4th St
Website
Grizz's Power House Gym
GYM
4.6 on Google · 27 reviews
211 E 7th St
Website
Hanford Crossfit
GYM
5.0 on Google · 24 reviews
730 Vaughn St
Website
Athletic Tilted Facility
GYM
4.1 on Google · 18 reviews
700 N 11th Ave
Website
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize the SURMOUNT weight-management program and the SURPASS diabetes program, including the SURPASS-2 head-to-head against semaglutide. Figures are means at each trial's primary endpoint.

SURMOUNT-1 randomized 2,539 adults with obesity (without diabetes) across 72 weeks. Mean weight change was −15.0% (5 mg), −19.5% (10 mg), and −20.9% (15 mg) versus −3.1% with placebo. A majority of patients on the higher doses lost ≥20% of body weight.[2]
STEP / SELECT endpoint table2.4 mg / 68 wk
Mean weight change (15 mg)
−20.9%
SURMOUNT-1, 72 wk vs −3.1% placebo[2]
Mean weight change (5 mg)
−15.0%
SURMOUNT-1, 72 wk[2]
HbA1c reduction (T2D)
−1.8 to −2.6%
SURPASS program[4]
vs. semaglutide 1 mg
Superior
SURPASS-2, HbA1c + weight[3]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average tirzepatide weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Boxed warning: risk of thyroid C-cell tumors. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
12 to 24%
mild
Dose-dependent; usually eases after titration
Diarrhea
12 to 19%
mild
More frequent during dose escalation
Vomiting
5 to 13%
mild
Reduced by slower titration
Constipation
6 to 17%
mild
Decreased appetite
5 to 11%
mild
Expected pharmacologic effect
Pancreatitis
<0.3%
serious
Discontinue if acute pancreatitis is suspected
Gallbladder disease
~1 to 2%
serious
Cholelithiasis risk rises with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated with MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Cash, Zepbound (no insurance)
$1,000 to $1,300
per month
Brand-name retail; Lilly self-pay vials lower for some doses[6]
Cash, Mounjaro (no insurance)
$1,000 to $1,200
per month
Brand-name retail average[6]
Commercial insurance (T2D)
$25 to $250
per month copay
Usually covered for diabetes with prior authorization
Commercial insurance (weight)
Often denied
Zepbound is on-label but frequently requires PA
Medicare Part D
$0 to $100
per month
T2D covered; weight-loss indication not covered by law[5]
Manufacturer savings card
as low as $25
per month
Commercial insurance only; eligibility limits apply
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Tirzepatide providers in California

NPI-verified Tirzepatide (tirzepatide) prescribers and clinics, never ranked by who pays us.

Tirzepatide in other states

Find NPI-verified Tirzepatide (tirzepatide) doctors, clinics, and pharmacies in the states we cover, never ranked by who pays us.

Related GLP-1 research
§ 09Frequently asked: Tirzepatide in California

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

Yes. Tirzepatide is the active molecule in both Eli Lilly products. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management. They are the same drug with different approved indications, and insurers treat them as separate products.[1]